Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia 10Breast Neoplasms 10Melanoma 9Congenital Abnormalities 9Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Neuroblastoma 4Neoplasms, Plasma Cell 4Myeloproliferative Disorders 4Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Head and Neck Neoplasms 4Carcinoma, Ovarian Epithelial 4Squamous Cell Carcinoma of Head and Neck 3Primary Myelofibrosis 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Pancreatic Neoplasms 3

Interventions

aldesleukin 26Sunitinib 25Interferon-alpha 21Everolimus 18Sorafenib 16Cyclophosphamide 16Filgrastim 13Bevacizumab 13Nivolumab 11Gemcitabine 11Interleukin-2 10Axitinib 10fludarabine phosphate 9Gene Expression Profiling 9temsirolimus 8Peripheral Blood Stem Cell Transplantation 8Doxorubicin 8pembrolizumab 7Radiotherapy 6Radiosurgery 6Polymerase Chain Reaction 6Ipilimumab 6Carboplatin 6sargramostim 5Ifosfamide 5Fluorouracil 5Erlotinib Hydrochloride 5Capecitabine 5Bortezomib 5atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Kidney Neoplasms × Immunologic Techniques × Clear all
NCT00900276 2018-07-05

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

Wake Forest University Health Sciences

Completed
5 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡